Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:02 AM
Ignite Modification Date:
2025-12-25 @ 12:02 AM
NCT ID:
NCT05065658
Eligibility Criteria:
Inclusion Criteria:
* Adult patient (\> 18 years)
* PCR (polymerase chain reaction) -confirmed SARS-CoV-2 infections based on nasopharyngeal swab (NPS), oropharyngeal swab (OPS), tracheal aspirate (TA), bronchial aspirate (BA), or bronchoalveolar lavage fluid (BALF) within 14 days prior to ICU admission or within 72 hours following ICU admission due to severe COVID-19 infection
* Radiographic imaging consistent with SARS-CoV-2 infection (e.g. atypical pneumonia, organizing pneumonia, ground glass opacities) or ARDS within 7 days of diagnosis of SARS-CoV-2 infection
Exclusion Criteria:
* Patients with a diagnosis of invasive aspergillosis/detection of Aspergillus spp. by culture from sputum, TA, BA, or BALF or positive GM from serum, TA, or BALF at baseline (=ICU admission)
* History of invasive aspergillosis within the prior six months
* Patients that are being treated with mold-active antifungal agents for invasive aspergillosis or another invasive fungal infection
* Patients that are being treated with mold-active antifungal agents for invasive aspergillosis or another invasive fungal infection
* Death or transfer to general ward within 48 hours of ICU admission
* Antifungal prophylaxis other than posaconazole (e.g. inhaled amphotericin B)
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05065658
Study Brief:
Protocol Section:
NCT05065658